← Back to Search

Other

LY3305677 for Obesity

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 72 hours postdose

Summary

This trial aims to test the safety of a new drug, LY3305677, in people who are obese or overweight. Participants will receive injections under the skin and undergo blood tests to see how their bodies handle the drug. The study will last several months for each participant.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 72 hours postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 72 hours postdose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3305677
Pharmacodynamics (PD): Percentage change in Body Weight
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3305677

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3305677Experimental Treatment1 Intervention
LY3305677 administered subcutaneously (SC)
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered SC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3305677
2017
Completed Phase 1
~180

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,675 Previous Clinical Trials
3,463,951 Total Patients Enrolled
69 Trials studying Obesity
45,615 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,388 Previous Clinical Trials
427,346 Total Patients Enrolled
51 Trials studying Obesity
25,157 Patients Enrolled for Obesity
~11 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top